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Concise Communication

A national survey of testing and management of asymptomatic
carriage of C. difficile
Preeta K. Kutty MD, MPH1, Susan E. Beekmann RN, MPH2,3, Ronda L. Sinkowitz-Cochran MPH1,
Erik R. Dubberke MD, MSPH4, David T. Kuhar MD1, L. Clifford McDonald MD1 and Philip M. Polgreen MD2,3
1

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, 2Infectious Disease Society of America Emerging
Infections Network, Arlington, Virginia, 3University of Iowa Carver College of Medicine, Iowa City, Iowa and 4Washington University, St Louis, Missouri

Abstract
A nationwide survey indicated that screening for asymptomatic carriers of C. difficile is an uncommon practice in US healthcare settings.
Better understanding of the role of asymptomatic carriage in C. difficile transmission, and of the measures available to reduce that risk,
are needed to inform best practices regarding the management of carriers.
(Received 29 November 2018; accepted 6 April 2019)

Recognized as one of the most important pathogens in healthcare
settings, Clostridioides difficile resulted in half a million infections
among US inpatients in 2011.1 Although much is known about the
contribution of symptomatic patients to transmission of C. difficile
in healthcare settings, asymptomatic C. difficile colonization has
recently garnered attention as a potential reservoir for transmission. Asymptomatic carriage is being increasingly recognized
among hospitalized adults, which has resulted in anecdotal reports
of identification and isolation of these patients despite a lack of recommendations on testing or management. We conducted a survey
to assess current clinical testing practices for asymptomatic carriers
of C. difficile and to determine whether such testing is common.
Methods
The Infectious Diseases Society of America (IDSA) Emerging
Infections Network (EIN) is a provider-based emerging infections
sentinel network,2 which is funded by the Centers for Disease
Control and Prevention (CDC) and sponsored by the IDSA. EIN
surveyed 1,309 US-based adult infectious disease specialists from
November 29 through December 23, 2017. Two reminders followed
an initial invitation by e-mailed link or faxed paper copy to nonresponders. No incentive for participation was provided. A confidential
9-question multiple choice/open-ended survey contained questions
regarding identification of patients with asymptomatic carriage of C.
difficile, isolation, and management. Data analysis was performed
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with SAS version 9.4 software (SAS Institute, Cary, NC). For
open-ended questions, comments were systematically reviewed,
coded for relevant themes, and grouped into categories.
Results
A total of 679 EIN physician members completed the survey, for a
response rate of 52%. Of these, 105 respondents (15%) indicated
that they had not seen patients with symptomatic CDI in the past
6 months and were excluded from further analysis; none of these
105 respondents reported testing asymptomatic patients. The
remaining 574 (85%) respondents indicated that they had seen
patients with symptomatic C. difficile infection (CDI) in the past
6 months. Of these, 166 (29%) worked in a hospital with >600 hospital beds, and 523 (91%) indicated that the nucleic acid amplification test (NAAT) was either conducted as a single step or in
multistep algorithm laboratory testing for symptomatic C. difficile
(Table 1). Of the 574 respondents, 22 (4%) indicated testing
patients for asymptomatic carriage of C. difficile. Of these 22
respondents, 36% practiced in university-affiliated hospitals and
32% in >600 bed hospitals (Table 1).
Of those who reported testing patients to detect asymptomatic
carriers, the reasons for screening included (1) being cared for on
selected units (n = 11, 50%) such as intensive care and oncology/
hematopoietic cell transplant units, having a previous history of
CDI (n = 5, 23%), (2) being in long-term care prior to admission
(n = 4, 18%), and (3) being part of a hospital-wide nonselective
screening approach (n = 4, 18%). Rectal swab (n = 11, 50%)
was the most common specimen tested. Once asymptomatic carriage of C. difficile was detected, contact precautions were most
often instituted, followed by enhanced environmental cleaning
(Fig. 1). Of those who reported using antibiotic prophylaxis
(n = 10) in detected asymptomatic carriers, oral vancomycin
(80%) was the most commonly used antibiotic. The most common
reasons for prescribing antibiotic prophylaxis included use of other
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Table 1. Characteristics of Respondents and Those That Responded
Affirmatively to Testing for Asymptomatic Patients, EIN Survey, 2017

Table 1. (Continued )

Respondents
(n = 574),
No. (%)

Responded
Affirmatively to Testing
for Asymptomatic
C. difficile (n = 22),
No. (%)

Combined EIA for
glutamate dehydrogenase
(GDH) assay and toxin

15 (3)

2 (9)

8 (1)

1 (5)

6 (27)

GDH EIA followed by cell
cytotoxicity neutralization
assay or toxin

148 (26)

5 (23)

Not sure

9 (2)

0

VA hospital or DOD

37 (7)

1 (5)

City/Council hospital

30 (5)

2 (9)

52 (9)

1 (5)

Respondents
(n = 574),
No. (%)

Responded
Affirmatively to Testing
for Asymptomatic
C. difficile (n = 22),
No. (%)

University hospital

190 (33)

8 (36)

Community hospital

169 (29)

Non-university teaching
hospital

Variable
Practice Characteristics
Type of Hospital

Note. VA, Veterans Affairs; DOD, Department of Defense; NAAT, nucleic acid amplification test;
PCR, polymerase chain reaction; LAMP, loop-mediated isothermal amplification EIA, enzyme
immunoassay; GI, gastrointestinal; GDH, glutamate dehydrogenase.

Region
New England
Mid Atlantic

78 (13)

2 (9)

East North Central

80 (14)

10 (45)

West North Central

55 (10)

0

South Atlantic

102 (18)

0

East South Central

30 (5)

0

West South Central

36 (6)

1 (5)

Mountain

26 (5)

2 (9)

113 (20)

6 (27)

2 (0.4)

0

<200

63 (11)

3 (14)

200–350

138 (24)

3 (14)

Pacific
Puerto Rico

92 (16)

4 (18)

451–600

115 (20)

5 (22)

>600

166 (29)

7 (32)

Survey Answers
Approximately how many patients with symptomatic CDI have you seen
in the past 6 months?
1–10

196 (34)

6 (27)

11–25

232 (40)

6 (27)

26–50

99 (17)

5 (23)

>50

47 (8)

5 (23)

8 (1)

1 (5)

310 (54)

11 (50)

11 (2)

0

213 (37)

7 (31)

Type of testing for symptomatic CDI
Single test
C. difficile included in
a GI panel of multiple
pathogens
NAAT only, eg, PCR or LAMP
EIA for toxin only
Multistep test
Combination of NAAT
(including GI panel) and
other tests (eg, GDH, EIA,
toxigenic culture)

antibiotics (50%) and because carriage was identified (40%).
Among asymptomatic carriers who developed diarrhea (n = 18),
repeat C. difficile testing was performed in 44%; empiric treatment
without repeat testing was started in 39%.
Discussion

Hospital bed size

351–450

Variable

(Continued)

A nationwide survey among US infectious disease physicians indicated that screening for asymptomatic carriers for C. difficile
among hospitalized adults was uncommon. The low occurrence
of screening for asymptomatic carriers may be indicative of uncertainty regarding their contribution to transmission, lack of data on
how to act on this information, and costs associated with active
surveillance. In addition, at the time of the survey, the guidelines
recommended neither detection nor management of such
patients.3 The current 2017 IDSA/SHEA guidelines reiterate this
recommendation.1
Prevalence of asymptomatic colonization in the community
settings has varied from 0% to 18% among healthy adults.4,5 In
acute-care settings, colonization has ranged from 5% to 21%,
and in long-term care facilities colonization has ranged from 0%
to 51%.6,7 Approximately 15% of asymptomatic carriers receive
the diagnosis of CDI.1 Based on the existing but limited information, the incubation period is considered relatively short in most
patients. However, the etiology of diarrhea in previously asymptomatic carriers, whether due to C. difficile or other causes, may be
unclear. Additionally, asymptomatic carriers, including those who
have recovered from CDI but remain colonized, may have developed antibodies that protect them from the effects of C. difficile
toxins, but may still serve as a potential reservoir for transmission
to others within a healthcare setting and in the community.7,8
The most common reasons reported for screening in this survey
were concerns about CDI in vulnerable patient populations (intensive care units, oncology and/or HCT units, previous history of
CDI) and the previous location where the patient resided. The survey did not ask at what point during the patient’s hospital care that
screening was performed. Although real-time interventional studies are scarce, mathematical modeling studies predict that screening for C. difficile carriage on admission could mitigate healthcareassociated CDI (HA-CDI) when bundled with other prevention
measures.8,9 A single-center quasi-experimental study by
Longtin et al8 demonstrated a 62% reduction in the rates of CDI
after implementing an active surveillance protocol. In a recent
study of outbreaks, the same authors did not find a difference in
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Fig. 1. Reported interventions when asymptomatic C. difficile carriers were detected, Emerging Infections Network Survey, 2017 (n = 22).

rates when screening was instituted.10 Currently, patient screening
either at the time of hospital admission or during hospitalization is
not recommended.1 Although rectal swabs were the most commonly reported screening specimen, often the perirectal swab is
used. Perirectal swab samples have 70%–99% sensitivity for the
detection of C. difficile colonization, which is comparable with
rectal swab samples; however, perirectal swabs are less invasive
and may be used in patients with neutropenia.7
Of concern is the use of antibiotics in carriers. As mentioned
earlier, at the time of this survey, the 2014 Strategies update recommended against treatment or decolonization of asymptomatic carriers.3 This has been reiterated in the recent IDSA/
SHEA updated clinical practice guidelines, which recommend
against treatment if such a patient were to be identified due
to the lack of evidence.1 Treatment of carriers failed to show
benefit in eradicating disease or reducing rates of HA-CDI
and studies suggest that oral vancomycin may be particularly
disruptive to the microbiome and may increase the risk for
CDI once stopped.11
The results of this survey may not be generalizable because
the survey was sent to EIN members who may not be representative of the majority of infectious disease physicians. In addition,
self-reported responses may be subject to bias.
Screening to detect asymptomatic carriers appears to be an
uncommon practice. Future studies that improve our understanding of asymptomatic C. difficile carrier epidemiology (including
burden), risk they pose for transmission (eg, duration of shedding,
contagiousness, infectious dose), and of the effects of interventions
that might prevent transmission to others (eg, transmission-based
precautions, use of antibiotics, and unintended consequences)
may better inform those who identify and manage these patients,
and how these patients impact transmission within healthcare
settings.
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